Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial

Oana Bulilete, Alfonso Leiva, Manuel Rullán, Antonia Roca, Joan Llobera, PHN Group, Oana Bulilete, Alfonso Leiva, Manuel Rullán, Antonia Roca, Joan Llobera, PHN Group

Abstract

Background: Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ). Previous trials have reported that gabapentin can relieve chronic neuropathic pain, but its effect on prevention of PHN is unclear.

Objective: To assess the efficacy of a 5-week course of gabapentin on acute herpetic pain and on the prevention of PHN at 12 weeks in patients with acute HZ.

Methods: This was a randomized, double blind, placebo-controlled trial conducted in 17 primary care health centers in Mallorca, Spain. All patients were older than 50 years, presented with HZ within 72 h of rash onset, and had moderate-severe pain (≥4 on a 10-point visual analogue scale [VAS]). Ninety-eight patients were randomized to receive gabapentin or placebo. All patients received valaciclovir for 7 days and analgesia if needed. The treatment period was 5 weeks, followed by 7 weeks of follow-up. Gabapentin was initiated at 300 mg/day and gradually titrated to a maximum of 1800 mg/day. The main outcome measure was pain at 12 weeks.

Results: Seventy-five patients completed the study, 33 in the gabapentin group and 42 in the control group. A total of 18.2% of patients in the gabapentin group and 9.5% in the control group reported pain at 12 weeks (p = 0.144). Four patients in the gabapentin group (12.1%), but no patients in the placebo group, reported pain of 4 or more on a 10-point VAS. Patients taking gabapentin reported worse health-related quality of life and poorer sleep quality. Three patients discontinued the trial due to adverse effects from gabapentin.

Conclusion: Addition of gabapentin to the usual treatment of HZ within 72 h of rash onset provided no significant relief from acute herpetic pain or prevention of PHN.

Trial registration: ISRCTN Registry identifier: ISRCTN79871784.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Study design and patient disposition…
Fig 1. Study design and patient disposition (CONSORT flow diagram).
Fig 2. Dose titration scheme during the…
Fig 2. Dose titration scheme during the 1st week of the study.

References

    1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014. June 10;4(6):e004833–e004833. 10.1136/bmjopen-2014-004833
    1. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010. December 21;8(1):37.
    1. Erskine N, Tran H, Levin L, Ulbricht C, Fingeroth J, Kiefe C, et al. A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events. PLoS One. 2017. July 27;12(7):e0181565 10.1371/journal.pone.0181565
    1. Gan EY, Tian EAL, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013. April 2;14(2):77–85. 10.1007/s40257-013-0011-2
    1. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013. September 3;81(10):928–30. 10.1212/WNL.0b013e3182a3516e
    1. Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T, et al. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145(13):2666–77. 10.1017/S0950268817001546
    1. Johnson RW, Alvarez-Pasquin M-J, Bijl M, Franco E, Gaillat J, Clara JG, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015. Jul 19;3(4):109–20. 10.1177/2051013615599151
    1. Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2015. January;157(1):30–54.
    1. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain. 2014. April;155(4):654–62. 10.1016/j.pain.2013.11.013
    1. Johnson RW, Rice ASC. Postherpetic Neuralgia. N Engl J Med. 2014. October 16;371(16):1526–33. 10.1056/NEJMcp1403062
    1. Tontodonati M, Ursini T, Polilli E, Vadini F, Di Masi F, Parruti G. Post-herpetic neuralgia. Int J Gen Med. 2012. October;5:861 10.2147/IJGM.S10371
    1. van Wijck AJM, Aerssens YR. Pain, itch, quality of life, and costs after herpes zoster. Pain Pract. 2017. July;17(6):738–46. 10.1111/papr.12518
    1. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia In: He L, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2009. p. CD006866 10.1002/14651858.CD006866.pub2
    1. Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia In: He L, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2010. p. CD005582 10.1002/14651858.CD005582.pub3
    1. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997. June;13(6):327–31.
    1. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9. 10.1093/cid/ciu918
    1. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med. 2015;372(22):2087–96. 10.1056/NEJMoa1501184
    1. Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience. 2016. December 3;338:183–206. 10.1016/j.neuroscience.2016.06.057
    1. Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci. 2004. April 9;74(21):2619–26. 10.1016/j.lfs.2004.01.005
    1. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016. April;4(2):e00205 10.1002/prp2.205
    1. Werner RN, Nikkels AF, Marinović B, Schäfer M, Czarnecka-Operacz M, Agius AM, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster—guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatology Venereol. 2017. January;31(1):20–9.
    1. Rullán M, Bulilete O, Leiva A, Soler A, Roca A, González-Bals MJ, et al. Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. Trials. 2017. December 14;18(1):24 10.1186/s13063-016-1729-y
    1. World Health Organization. WHO’s cancer pain ladder for adults [Internet]. World Health Organization; 1986. Available from:
    1. Perez C, Galvez R, Huelbes S, Insausti J, Bouhassira D, Diaz S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007. December 4;5(1):66.
    1. European Medicines Agency. Guideline on the clinical development of medicinal products intended for the treatment of pain [Internet]. 2016. Available from:
    1. Vilagut G, Valderas JM, Ferrer M, Garin O, López-García E, Alonso J. Interpretación de los cuestionarios de salud SF-36 y SF-12 en España: Componentes físico y mental. Med Clin (Barc). 2008. May 24;130(19):726–35.
    1. Rejas J, Ribera MV, Ruiz M, Masrramón X. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain. 2007. April;11(3):329–40. 10.1016/j.ejpain.2006.05.002
    1. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Heath,Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
    1. James KE, Block DA, Lee KK, Kraemer HC, Fuller RK. An index for assessing blindness in a multi-centre clinical trial: Disulfiram for alcohol cessation—A VA cooperative study. Stat Med. 1996. July 15;15(13):1421–34. 10.1002/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>;2-H
    1. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004. April;25(2):143–56. 10.1016/j.cct.2003.10.016
    1. Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain. 2007. March;128(1–2):148–56. 10.1016/j.pain.2006.09.021
    1. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013. March 24;36(3):237–51. 10.1007/s12272-013-0057-y
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015. February;14(2):162–73. 10.1016/S1474-4422(14)70251-0
    1. Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017. June 9;(6):CD007938.
    1. Johnson P, Becker L, Halpern R, Sweeney M. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013. January 23;33(1):35–44. 10.1007/s40261-012-0030-4
    1. Lee EG, Lee HJ, Hyun DJ, Min K, Kim DH, Yoon MS. Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study. Dermatol Ther. 2016. May;29(3):184–90. 10.1111/dth.12331
    1. Lapolla W, DiGiorgio C, Haitz K, Magel G, Mendoza N, Grady J, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: Open-label study. Arch Dermatol. 2011. August 1;147(8):901–7. 10.1001/archdermatol.2011.81
    1. Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009. April;142(3):209–17. 10.1016/j.pain.2008.12.022
    1. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology. 2005;65(3):444–7. 10.1212/01.wnl.0000168259.94991.8a
    1. Singh S, Madhwar A, Singh JP. Comparative study of gabapentin in combination with valacyclovir and valacyclovir alone in herpes zoster. Int J Sci fic Study. 2016;3(11):37–40.
    1. Kanodia S, Seth A, Dixit A. Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients. Indian J Dermatol. 2012. September;57(5):362 10.4103/0019-5154.100476
    1. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain—Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017. August 3;377(5):411–4. 10.1056/NEJMp1704633
    1. Centers for Disease Control and Prevention. Shingles | For Health Care Professionals | Herpes Zoster [Internet]. 2018. Available from:
    1. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018. January 26;67(3):103–8. 10.15585/mmwr.mm6703a5
    1. Carroll S, Gater A, Abetz-Webb L, Smith F, Demuth D, Mannan A. Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: Learnings from the Zoster Quality of Life (ZQOL) study. BMC Res Notes. 2013. November 25;6(1):486.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する